Two Posters and Two Oral Presentations on NOXXON Pharma AG Compounds at 2012 American Society of Hematology Conference
12/6/2012 10:57:53 AM
More...
|
NOXXON Pharma AG Initiates Phase IIa of Anti-Hepcidin Spiegelmer® NOX-H94
12/4/2012 10:45:45 AM
More...
|
NOXXON Pharma AG Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer®
9/26/2012 9:29:10 AM
More...
|
NOXXON Pharma AG Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer® NOX-A12 for Treatment of Chronic Lymphocytic Leukemia
7/11/2012 9:56:42 AM
More...
|
NOXXON Pharma AG Initiates Phase IIa of anti-CCL2/MCP-1 Spiegelmer NOX-E36 for Treatment of Diabetic Nephropathy
6/19/2012 11:32:31 AM
More...
|
NOXXON Pharma AG's NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model
4/4/2012 9:30:04 AM
More...
|
NOXXON Pharma AG to Present at 30th Annual J.P. Morgan Healthcare Conference
1/6/2012 9:26:42 AM
More...
|
NOXXON Pharma AG's SDF-1 inhibitor NOX-A12 Completes Phase I
12/12/2011 11:06:28 AM
More...
|
NOXXON Pharma AG initiates Phase I of NOX-H94 for Anemia of Chronic Disease
9/6/2011 9:52:19 AM
More...
|
NOXXON Pharma AG to Exhibit at 2011 Biotechnology Industry Organization (BIO) International Convention, Jun 27 - 30, 2011
6/24/2011 9:31:01 AM
More...
|
|